NEW YORK – A long-standing development effort has come to fruition for Cepheid which this week debuted its 10-color molecular diagnostic testing technology in a new assay to help diagnose and profile extensively drug-resistant tuberculosis and select the best treatment.
Developed in collaboration with researchers at Rutgers University and with guidance and support from the Foundation for Innovative New Diagnostics, the test is now CE-IVD marked and the Danaher subsidiary said it expects to roll it out with assistance from FIND and the World Health Organization.